预防公卫

订阅

MedSci主页 / 所有栏目 / 预防公卫

中国内地首次检出奥密克戎变异株，从天津流入

2021-12-13 MedSci原创 MedSci原创

奥密克戎
关注

12月13日从天津市疫情防控指挥部获悉，市疾病预防控制中心对12月9日我市境外输入新冠病毒无症状感染者呼吸道标本进行新冠病毒全基因组测序和序列分析，经中国疾病预防控制中心复核，均确认检出新冠病毒奥密克

12月13日从天津市疫情防控指挥部获悉，市疾病预防控制中心对12月9日我市境外输入新冠病毒无症状感染者呼吸道标本进行新冠病毒全基因组测序和序列分析，经中国疾病预防控制中心复核，均确认检出新冠病毒奥密克戎变异株（B.1.1.529进化分支）。在津感染者系入境闭环管控人员，目前于定点医院隔离治疗。据悉，这是中国内地首次发现新冠病毒奥密克戎变异株。

广大公众应继续保持良好的卫生习惯，坚持科学佩戴口罩、接种疫苗、勤洗手、不聚集等有效的防控措施，特别是3至11岁儿童、60岁以上老年人要积极配合新冠疫苗接种工作，入境人员、高风险岗位人员、重点疫情地区人员返津后要主动申报，配合做好健康监测及分类管理，要坚持非必须不出境，减少不必要出行，毫不松懈、共同抵御新冠病毒变异株带来的风险。

此前，11.25的时候，奥密克戎就已经登陆中国香港；12月11日，中国台湾地区流行疫情指挥中心公布，中国台湾出现首例奥密克毒株感染病例。

目前奥密克戎已传播至全球近70个国家和地区。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1342935, encodeId=4ac213429354a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Dec 15 13:21:21 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079836, encodeId=899810e983677, content=疗是许多肿瘤治疗的重要手段，化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:57 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079812, encodeId=e4aa10e98125e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8d15446486, createdName=ms2000001444805194, createdTime=Tue Dec 14 08:31:30 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079774, encodeId=532610e9774d0, content=不容忽视, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Dec 14 06:23:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079767, encodeId=fa0a10e9767ee, content=要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210407/519faa55f00c4b649ac2cd5ec01e86db/50166abc71364299b469a15c9aeb9dfd.jpg, createdBy=18731971351, createdName=云水鱼, createdTime=Tue Dec 14 01:03:43 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-15 12498dabm77暂无昵称

    #变异#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1342935, encodeId=4ac213429354a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Dec 15 13:21:21 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079836, encodeId=899810e983677, content=疗是许多肿瘤治疗的重要手段，化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:57 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079812, encodeId=e4aa10e98125e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8d15446486, createdName=ms2000001444805194, createdTime=Tue Dec 14 08:31:30 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079774, encodeId=532610e9774d0, content=不容忽视, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Dec 14 06:23:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079767, encodeId=fa0a10e9767ee, content=要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210407/519faa55f00c4b649ac2cd5ec01e86db/50166abc71364299b469a15c9aeb9dfd.jpg, createdBy=18731971351, createdName=云水鱼, createdTime=Tue Dec 14 01:03:43 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 查查佳佳

    疗是许多肿瘤治疗的重要手段，化疗相关毒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1342935, encodeId=4ac213429354a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Dec 15 13:21:21 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079836, encodeId=899810e983677, content=疗是许多肿瘤治疗的重要手段，化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:57 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079812, encodeId=e4aa10e98125e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8d15446486, createdName=ms2000001444805194, createdTime=Tue Dec 14 08:31:30 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079774, encodeId=532610e9774d0, content=不容忽视, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Dec 14 06:23:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079767, encodeId=fa0a10e9767ee, content=要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210407/519faa55f00c4b649ac2cd5ec01e86db/50166abc71364299b469a15c9aeb9dfd.jpg, createdBy=18731971351, createdName=云水鱼, createdTime=Tue Dec 14 01:03:43 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 ms2000001444805194

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1342935, encodeId=4ac213429354a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Dec 15 13:21:21 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079836, encodeId=899810e983677, content=疗是许多肿瘤治疗的重要手段，化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:57 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079812, encodeId=e4aa10e98125e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8d15446486, createdName=ms2000001444805194, createdTime=Tue Dec 14 08:31:30 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079774, encodeId=532610e9774d0, content=不容忽视, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Dec 14 06:23:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079767, encodeId=fa0a10e9767ee, content=要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210407/519faa55f00c4b649ac2cd5ec01e86db/50166abc71364299b469a15c9aeb9dfd.jpg, createdBy=18731971351, createdName=云水鱼, createdTime=Tue Dec 14 01:03:43 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 学医无涯

    不容忽视

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1342935, encodeId=4ac213429354a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Dec 15 13:21:21 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079836, encodeId=899810e983677, content=疗是许多肿瘤治疗的重要手段，化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:57 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079812, encodeId=e4aa10e98125e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8d15446486, createdName=ms2000001444805194, createdTime=Tue Dec 14 08:31:30 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079774, encodeId=532610e9774d0, content=不容忽视, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Dec 14 06:23:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079767, encodeId=fa0a10e9767ee, content=要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210407/519faa55f00c4b649ac2cd5ec01e86db/50166abc71364299b469a15c9aeb9dfd.jpg, createdBy=18731971351, createdName=云水鱼, createdTime=Tue Dec 14 01:03:43 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 云水鱼

    要重视

    0

相关资讯

五项针对奥密克戎（Omicron）突变株的血清学研究发布，在考虑“要不要换加强针？”

辉瑞/BioNTech公布的BNT162b2针对Omicron的血清学研究结果很让人失望，因为提示：“尽管3剂加强针后1个月时对Omicron有保护力，但2剂接种后3周时预防Omicron

2021年12月10日简报：多数奥密克戎变异株感染病例症状轻微，中国新冠特效药中和抗体获批上市

截至北京时间2021年12月10日7时01分，Worldometers世界实时统计数据显示，全球累计确诊新冠肺炎（COVID-19）病例超过2亿6870万例，新增601,434例，达到268,703,

2021年12月11日简报：南非奥密克戎几乎完全取代Delta感染，展示超强竞争力；全球多国奥密克戎感染病例骤增，在几天内成为主要流行毒株；奥密克戎可能不会导致严重疾病，仍需2-3周确定

截至北京时间2021年12月11日7时01分，Worldometers世界实时统计数据显示，全球累计确诊新冠肺炎（COVID-19）病例超过2亿6938万例，新增594,130例，达到269,382,

2021年12月12日简报：奥密克戎让大部分中和抗体失效，但是预计到明年春天，全球疫情全缓和

截至北京时间2021年12月12日7时01分，Worldometers世界实时统计数据显示，全球累计确诊新冠肺炎（COVID-19）病例超过2亿6995万例，新增488,458例，达到269,956,

中和抗体能对抗奥密克戎（Omicron）突变株吗？谢晓亮教授给您答案（附下载）

12月8日，国家药监局应急批准腾盛华创医药技术(北京)有限公司新冠病毒中和抗体联合治疗药物安巴韦单抗注射液及罗米司韦单抗注射液注册申请，用于新冠病毒感染的治疗，这是我国第一款治疗新冠的特效药。

2021年12月13日简报：国内新增本土病例49例，其中浙江38例；感染新冠可能会影响男性的生殖能力，南非一周的新增感染病例激增400%

截至北京时间2021年12月13日7时01分，Worldometers世界实时统计数据显示，全球累计确诊新冠肺炎（COVID-19）病例超过2亿7040万例，新增488,458例，达到270,400,